NASDAQ
6.80USD
-0.09 (-1.31%)
We have scored 27 news catalysts on Entrada Therapeutics, Inc. (TRDA) over the past 12 months. The biggest single-day move next to one of them came May 18, 2026, when TRDA closed −7.7%: “TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm”. Coverage across the window leans negative (average ticker sentiment −0.61). Most of the impact sits in price momentum and earnings revision trend.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
264M
P/E
—
EPS
—
Beta
-0.25
52W range
5.08-16.45
Day range
6.78–6.95
Open
6.91
Prev close
6.89
Volume
221.1K
Avg volume
427.8K
Dividend
0.00
IPO
2021-10-29
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Entrada Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for TRDA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
